Retinoic acid receptor beta is also identified as RAR-beta and NR1B2 stands for nuclear receptor subfamily 1, group B, member 2. RAR-beta is a nuclear receptor which in individuals is determined by RARB gene. This genetic material encodes RAR-beta, of nuclear transcriptional regulators with an adherent super family of thyroid-steroid hormone receptor. This receptor localizes to sub nuclear compartments and to cytoplasm. It is assumed that this protein restricts growth of countless cell types by controlling gene manifestation.

Market Dynamics

Progression in the genetic science related R&D and technical advancements are driving the growth of retinoic acid receptor beta market. However, low acceptance and lack of awareness about its benefits are major factors halting the market growth. Constant discoveries and development in medical science combined with development in medical infrastructural initiatives by delegates globally especially in application such as metabolic disorders, hemotological disorders, oncology are posing lucrative growth opportunity in coming years.

Market Classification

The market can be bifurcated on the basis of product, application and geography. By product, retinoic acid receptor beta market can be segmented into alitretinoin, SBD-073, tamibarotene, tazarotene and others. By application, retinoic acid receptor beta market can be segmented into metabolic disorders, hemotological disorders, oncology and others. On the basis of geography, the retinoic acid receptor beta market can be segmented into North America, Latin America, Europe, Middle East & Africa (MEA) and Asia-Pacific.

Report Coverage

Market Participants

Some of the major players involved in retinoic acid receptor beta market include Lee’s Pharmaceutical Holdings Ltd, Promius Pharma LLC, Phosphagenics Ltd, Valeant Pharmaceuticals International Inc and Sol-Gel Technologies Ltd among others.

Market Segmentation

Market By Product

• Alitretinoin
• SBD-073
• Tamibarotene
• Tazarotene
• Others

Market By Application

• Metabolic Disorders
• Hemotological Disorders
• Oncology
• Others

Market By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • France
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of LATAM
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA